Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026

Experts Are Sounding the Alarm Over an AI Bubble. Here's What History Says Investors Should Do Right Now.

View original at nasdaq.com
Experts Are Sounding the Alarm Over an AI Bubble. Here's What History Says Investors Should Do Right Now. Key Points The AI industry has been wavering lately, as fears around a bubble grow…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The top 10 largest AI-related stocks now make up over 40% of the S&P 500, similar to tech stock concentration during the dot-com bubble of the early 2000s.

    60% confidence
  • Fund managers identified an AI bubble as the most pressing tail risk facing the market right now.

    60% confidence
  • 61% of fund managers don't expect hyperscalers to cut back on AI spending this year.

    60% confidence
  • History suggests that during a bear market, overhyped and overvalued stocks with unsustainable business models, poor financial health, or weak competitive advantages will struggle the most, while companies built on solid foundations will eventually recover.

    60% confidence

Data points we hold from this source

S&P 500 Index Fund · total return206 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com